Reuters logo
BRIEF-Helix Biopharma accelerates escalation of L-DOS47 dosing in the U.S. Phase I study
2016年11月30日 / 下午12点47分 / 1 年前

BRIEF-Helix Biopharma accelerates escalation of L-DOS47 dosing in the U.S. Phase I study

Nov 30 (Reuters) - Helix Biopharma Corp

* Helix Biopharma Corp accelerates escalation of L-DOS47 dosing in the U.S. Phase I study

* Helix Biopharma - U.S. FDA has accepted accelerated escalation for L-DOS47 dosing in U.S. Phase I study up to 12g/kg in combination with pemetrexed/carboplatin Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below